U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Myeloproliferative disorder

MedGen UID:
10147
Concept ID:
C0027022
Neoplastic Process
Synonym: Myeloproliferative disease
SNOMED CT: Myeloproliferative disorder (414794006); Myeloproliferative disorder (425333006); Proliferation of myeloid cells (414794006); Myeloid proliferation (414794006)
 
HPO: HP:0005547

Definition

Proliferation (excess production) of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. [from HPO]

Conditions with this feature

Primary myelofibrosis
MedGen UID:
7929
Concept ID:
C0001815
Neoplastic Process
Primary myelofibrosis is a condition characterized by the buildup of scar tissue (fibrosis) in the bone marrow, the tissue that produces blood cells. Because of the fibrosis, the bone marrow is unable to make enough normal blood cells. The shortage of blood cells causes many of the signs and symptoms of primary myelofibrosis.\n\nInitially, most people with primary myelofibrosis have no signs or symptoms. Eventually, fibrosis can lead to a reduction in the number of red blood cells, white blood cells, and platelets. A shortage of red blood cells (anemia) often causes extreme tiredness (fatigue) or shortness of breath. A loss of white blood cells can lead to an increased number of infections, and a reduction of platelets can cause easy bleeding or bruising.\n\nBecause blood cell formation (hematopoiesis) in the bone marrow is disrupted, other organs such as the spleen or liver may begin to produce blood cells. This process, called extramedullary hematopoiesis, often leads to an enlarged spleen (splenomegaly) or an enlarged liver (hepatomegaly). People with splenomegaly may feel pain or fullness in the abdomen, especially below the ribs on the left side. Other common signs and symptoms of primary myelofibrosis include fever, night sweats, and bone pain.\n\nPrimary myelofibrosis is most commonly diagnosed in people aged 50 to 80 but can occur at any age.
Down syndrome
MedGen UID:
4385
Concept ID:
C0013080
Disease or Syndrome
Down syndrome is a chromosomal condition that is associated with intellectual disability, a characteristic facial appearance, and weak muscle tone (hypotonia) in infancy. All affected individuals experience cognitive delays, but the intellectual disability is usually mild to moderate.\n\nPeople with Down syndrome often have a characteristic facial appearance that includes a flattened appearance to the face, outside corners of the eyes that point upward (upslanting palpebral fissures), small ears, a short neck, and a tongue that tends to stick out of the mouth. Affected individuals may have a variety of birth defects. Many people with Down syndrome have small hands and feet and a single crease across the palms of the hands. About half of all affected children are born with a heart defect. Digestive abnormalities, such as a blockage of the intestine, are less common.\n\nIndividuals with Down syndrome have an increased risk of developing several medical conditions. These include gastroesophageal reflux, which is a backflow of acidic stomach contents into the esophagus, and celiac disease, which is an intolerance of a wheat protein called gluten. About 15 percent of people with Down syndrome have an underactive thyroid gland (hypothyroidism). The thyroid gland is a butterfly-shaped organ in the lower neck that produces hormones. Individuals with Down syndrome also have an increased risk of hearing and vision problems. Additionally, a small percentage of children with Down syndrome develop cancer of blood-forming cells (leukemia).\n\nDelayed development and behavioral problems are often reported in children with Down syndrome. Affected individuals can have growth problems and their speech and language develop later and more slowly than in children without Down syndrome. Additionally, speech may be difficult to understand in individuals with Down syndrome. Behavioral issues can include attention problems, obsessive/compulsive behavior, and stubbornness or tantrums. A small percentage of people with Down syndrome are also diagnosed with developmental conditions called autism spectrum disorders, which affect communication and social interaction.\n\nPeople with Down syndrome often experience a gradual decline in thinking ability (cognition) as they age, usually starting around age 50. Down syndrome is also associated with an increased risk of developing Alzheimer's disease, a brain disorder that results in a gradual loss of memory, judgment, and ability to function. Approximately half of adults with Down syndrome develop Alzheimer's disease. Although Alzheimer's disease is usually a disorder that occurs in older adults, people with Down syndrome commonly develop this condition earlier, in their fifties or sixties.
Idiopathic hypereosinophilic syndrome
MedGen UID:
61525
Concept ID:
C0206141
Disease or Syndrome
PDGFRA-associated chronic eosinophilic leukemia is a form of blood cell cancer characterized by an elevated number of cells called eosinophils in the blood. These cells help fight infections by certain parasites and are involved in the inflammation associated with allergic reactions. However, these circumstances do not account for the increased number of eosinophils in PDGFRA-associated chronic eosinophilic leukemia.\n\nAnother characteristic feature of PDGFRA-associated chronic eosinophilic leukemia is organ damage caused by the excess eosinophils. Eosinophils release substances to aid in the immune response, but the release of excessive amounts of these substances causes damage to one or more organs, most commonly the heart, skin, lungs, or nervous system. Eosinophil-associated organ damage can lead to a heart condition known as eosinophilic endomyocardial disease, skin rashes, coughing, difficulty breathing, swelling (edema) in the lower limbs, confusion, changes in behavior, or impaired movement or sensations. People with PDGFRA-associated chronic eosinophilic leukemia can also have an enlarged spleen (splenomegaly) and elevated levels of certain chemicals called vitamin B12 and tryptase in the blood.\n\nSome people with PDGFRA-associated chronic eosinophilic leukemia have an increased number of other types of white blood cells, such as neutrophils or mast cells. Occasionally, people with PDGFRA-associated chronic eosinophilic leukemia develop other blood cell cancers, such as acute myeloid leukemia or B-cell or T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.\n\nPDGFRA-associated chronic eosinophilic leukemia is often grouped with a related condition called hypereosinophilic syndrome. These two conditions have very similar signs and symptoms; however, the cause of hypereosinophilic syndrome is unknown.
Myeloproliferative disease, autosomal recessive
MedGen UID:
338119
Concept ID:
C1850779
Disease or Syndrome
Myeloproliferative disorder, chronic, with eosinophilia
MedGen UID:
377060
Concept ID:
C1851585
Disease or Syndrome
PDGFRB-associated chronic eosinophilic leukemia is a type of cancer of blood-forming cells. It is characterized by an elevated number of white blood cells called eosinophils in the blood. These cells help fight infections by certain parasites and are involved in the inflammation associated with allergic reactions. However, these circumstances do not account for the increased number of eosinophils in PDGFRB-associated chronic eosinophilic leukemia. Some people with this condition have an increased number of other types of white blood cells, such as neutrophils or mast cells, in addition to eosinophils. People with this condition can have an enlarged spleen (splenomegaly) or enlarged liver (hepatomegaly). Some affected individuals develop skin rashes, likely as a result of an abnormal immune response due to the increased number of eosinophils.

Professional guidelines

PubMed

Nagatomo K, Fukushima H, Kanai Y, Muramatsu H, Takada H
Pediatr Int 2021 Dec;63(12):1521-1523. Epub 2021 Aug 5 doi: 10.1111/ped.14634. PMID: 34355465
Casavecchia G, Galderisi M, Novo G, Gravina M, Santoro C, Agricola E, Capalbo S, Zicchino S, Cameli M, De Gennaro L, Righini FM, Monte I, Tocchetti CG, Brunetti ND, Cadeddu C, Mercuro G
Heart Fail Rev 2020 May;25(3):447-456. doi: 10.1007/s10741-020-09926-y. PMID: 32026180
Sakashita K, Matsuda K, Koike K
Pediatr Int 2016 Aug;58(8):681-90. doi: 10.1111/ped.13068. PMID: 27322988

Recent clinical studies

Etiology

Noh HR, Magpantay GG
Allergy Asthma Proc 2017 Jan 1;38(1):78-81. doi: 10.2500/aap.2017.38.3995. PMID: 28052805
Poch Martell M, Sibai H, Deotare U, Lipton JH
Expert Rev Hematol 2016 Oct;9(10):923-32. doi: 10.1080/17474086.2016.1232163. PMID: 27590270
Lorsbach RB
Am J Clin Pathol 2004 Dec;122 Suppl:S33-46. doi: 10.1309/Y57UGTE36PGQ2NV6. PMID: 15690641
Stuart BJ, Viera AJ
Am Fam Physician 2004 May 1;69(9):2139-44. PMID: 15152961
Schafer AI
Curr Opin Hematol 1996 Sep;3(5):341-6. doi: 10.1097/00062752-199603050-00002. PMID: 9372099

Diagnosis

Moiz B, Shafiq M
Blood 2012 Dec 6;120(24):4672. doi: 10.1182/blood-2012-07-440917. PMID: 23350067
Sulai NH, Tefferi A
Hematol Oncol Clin North Am 2012 Apr;26(2):285-301, viii. doi: 10.1016/j.hoc.2012.01.003. PMID: 22463828
Lorsbach RB
Am J Clin Pathol 2004 Dec;122 Suppl:S33-46. doi: 10.1309/Y57UGTE36PGQ2NV6. PMID: 15690641
Stuart BJ, Viera AJ
Am Fam Physician 2004 May 1;69(9):2139-44. PMID: 15152961
Schafer AI
Curr Opin Hematol 1996 Sep;3(5):341-6. doi: 10.1097/00062752-199603050-00002. PMID: 9372099

Therapy

Reiner AS, Durham BH, Yabe M, Petrova-Drus K, Francis JH, Rampal RK, Lacouture ME, Rotemberg V, Abdel-Wahab O, Panageas KS, Diamond EL
Br J Haematol 2023 Nov;203(3):389-394. Epub 2023 Jul 3 doi: 10.1111/bjh.18964. PMID: 37400251Free PMC Article
Agashe RP, Lippman SM, Kurzrock R
Mol Cancer Ther 2022 Dec 2;21(12):1757-1764. doi: 10.1158/1535-7163.MCT-22-0323. PMID: 36252553Free PMC Article
Abbasian S, Shokrgozar N, Tamaddon G
Clin Lab 2021 May 1;67(5) doi: 10.7754/Clin.Lab.2020.200835. PMID: 33978360
Radich JP, Mauro MJ
Hematol Oncol Clin North Am 2017 Aug;31(4):577-587. doi: 10.1016/j.hoc.2017.04.006. PMID: 28673389
Skorski T
Curr Hematol Malig Rep 2012 Jun;7(2):87-93. doi: 10.1007/s11899-012-0114-5. PMID: 22328017

Prognosis

Crespiatico I, Zaghi M, Mastini C, D'Aliberti D, Mauri M, Mercado CM, Fontana D, Spinelli S, Crippa V, Inzoli E, Manghisi B, Civettini I, Ramazzotti D, Sangiorgio V, Gengotti M, Brambilla V, Aroldi A, Banfi F, Barone C, Orsenigo R, Riera L, Riminucci M, Corsi A, Breccia M, Morotti A, Cilloni D, Roccaro A, Sacco A, Stagno F, Serafini M, Mottadelli F, Cazzaniga G, Pagni F, Chiarle R, Azzoni E, Sessa A, Gambacorti-Passerini C, Elli EM, Mologni L, Piazza R
Blood 2024 Apr 4;143(14):1399-1413. doi: 10.1182/blood.2023021349. PMID: 38194688
Flis S, Chojnacki T
Drug Des Devel Ther 2019;13:825-843. Epub 2019 Mar 8 doi: 10.2147/DDDT.S191303. PMID: 30880916Free PMC Article
Radich JP, Mauro MJ
Hematol Oncol Clin North Am 2017 Aug;31(4):577-587. doi: 10.1016/j.hoc.2017.04.006. PMID: 28673389
Noh HR, Magpantay GG
Allergy Asthma Proc 2017 Jan 1;38(1):78-81. doi: 10.2500/aap.2017.38.3995. PMID: 28052805
Moiz B, Shafiq M
Blood 2012 Dec 6;120(24):4672. doi: 10.1182/blood-2012-07-440917. PMID: 23350067

Clinical prediction guides

Agashe RP, Lippman SM, Kurzrock R
Mol Cancer Ther 2022 Dec 2;21(12):1757-1764. doi: 10.1158/1535-7163.MCT-22-0323. PMID: 36252553Free PMC Article
Chatterjee A, Ghosh J, Kapur R
Oncotarget 2015 Jul 30;6(21):18250-64. doi: 10.18632/oncotarget.4213. PMID: 26158763Free PMC Article
Wautier JL, Wautier MP
Clin Hemorheol Microcirc 2013;53(1-2):11-21. doi: 10.3233/CH-2012-1572. PMID: 22941965
Naithani R, Tyagi S, Choudhry VP
J Pediatr Hematol Oncol 2008 Mar;30(3):196-8. doi: 10.1097/MPH.0b013e318161a9b8. PMID: 18376280
Barosi G, Hoffman R
Semin Hematol 2005 Oct;42(4):248-58. doi: 10.1053/j.seminhematol.2005.05.018. PMID: 16210038

Recent systematic reviews

Slouma M, Bouzid S, Tlili K, Yedaes D, Radhwen K, Gharsallah I
Clin Neurol Neurosurg 2024 Apr;239:108206. Epub 2024 Feb 29 doi: 10.1016/j.clineuro.2024.108206. PMID: 38461672
Janmohamed IK, Sondh RS, Ahmed H, Afzal MB, Tyson N, Harky A
Heart Lung Circ 2022 Mar;31(3):304-312. Epub 2021 Nov 15 doi: 10.1016/j.hlc.2021.10.012. PMID: 34794873

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...